UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder. ResMed makes continuous positive ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

The ResMed AirSense machines have a white-colored filter you replace every two weeks Replace the water tank that functions as the humidifier every six months. If your CPAP has an integrated or ...

ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...

or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...

Sleep apnea or other forms of the sleep disorder require an effective CPAP machine to enhance your health and sleep patterns. Surgeons use CPAP machines for sufferers of sleep apnea, which is a ...

ResMed has convinced investors that a reduction in obesity rates globally thanks to GLP-1 drugs such as Ozempic will not necessarily reduce demand for its ventilators and machines, which improve ...